PepJunkie Home of the Peptonauts
More

Peptide Atlas · Peptide

Pemvidutide

Pemvidutide is a GLP-1 and glucagon dual receptor agonist; in a 12-week randomized trial in 94 people with metabolic dysfunction-associated steatotic liver disease, weekly injections cut liver fat by 46.6% to 68.5% from baseline against 4.4% on placebo.

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.